Home › Funds › Logos Global Management LP › AVBP
Logos Global Management LP position in AVBP
ARRIVENT BIOPHARMA INC COM · Health Care
Logos Global Management LP reported holding 1,000,000 shares of AVBP (ARRIVENT BIOPHARMA INC COM) in its Q2 2026 13F filing — a position valued at US$34.7M, representing 1.50% of its reported portfolio and ranking #23 among its reported holdings. Logos Global Management LP has disclosed AVBP holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's AVBP position evolved
Logos Global Management LP first disclosed a stake in AVBP in Q1 2026 at 350,000 shares (US$8.1M). The position peaked in Q2 2026 at 1,000,000 shares, worth US$34.7M. Across 2 filings, Logos Global Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,000,000 shares valued at US$34.7M — an increase of 650,000 shares quarter over quarter.. Notable position changes include a 186% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 350.00K | $8.07M | New |
| Q2 2026 | 1.00M | $34.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC COM) is a Health Care company. 60 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), Hillhouse Capital (HHLR Advisors) (US$136.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.52M sh · $156.87M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.44M sh · $154.19M · Q2 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $136.50M · Q2 2026
- ORBIMED ADVISORS LLC 3.03M sh · $105.17M · Q2 2026
- Octagon Capital Advisors LP 1.97M sh · $68.47M · Q2 2026
- Sofinnova Investments, Inc. 1.70M sh · $58.95M · Q2 2026
- Vivo Capital, LLC 1.68M sh · $58.44M · Q2 2026
- Novo Holdings A/S 1.50M sh · $52.11M · Q2 2026
- General Catalyst Group Management, LLC 1.49M sh · $51.93M · Q2 2026
- HSG Holding Ltd 663.31K sh · $23.04M · Q2 2026
- Foresite Capital Management VI LLC 301.34K sh · $10.47M · Q2 2026
- Seven Fleet Capital Management LP 246.61K sh · $8.57M · Q2 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held AVBP?
Logos Global Management LP has disclosed AVBP holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Logos Global Management LP's current position in AVBP?
As of Q2 2026, Logos Global Management LP holds 1.00M shares of AVBP (ARRIVENT BIOPHARMA INC COM), valued at $34.74M, representing 1.50% of its reported portfolio and ranking #23.
Has Logos Global Management LP been buying or selling AVBP?
In the latest 13F filing (Q2 2026), Logos Global Management LP increased its position in AVBP. The position peaked in Q2 2026 at 1.00M shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.